Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 18, Issue 2, Pages 63-71
http://dx.doi.org/10.1155/2002/341708

Pharmacogenomic Biomarkers

Sandra C. Kirkwood and Richard D. Hockett Jr.

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

Received 18 September 2002; Accepted 18 September 2002

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [10 citations]

The following is the list of published articles that have cited the current article.

  • Sue A. Shapses, Yvette R. Schlussel, and Mariana Cifuentes, “Drug-Nutrient Interactions That Impact Mineral Status,” Handbook of Drug-Nutrient Interactions, pp. 301–328, 2004. View at Publisher · View at Google Scholar
  • T Efferth, and M Volm, “Pharmacogenetics for individualized cancer chemotherapy,” Pharmacology & Therapeutics, vol. 107, no. 2, pp. 155–176, 2005. View at Publisher · View at Google Scholar
  • M.G. Hamerski, M.A.T. Bortolini, I. D. C. Guerreiro Da Silva, R.A. Castro, M.G.F. Sartori, G. Rodrigues De Lima, and M.J.B.C. Girão, “Effect of tibolone on cytochrome c oxidase I, beta-2-microblobulin and vascular endothelial growth factor gene expression in the lower urinary tract of castrated rats,” Clinical and Experimental Obstetrics and Gynecology, vol. 33, no. 4, pp. 233–237, 2006. View at Publisher · View at Google Scholar
  • Michael Williams, “Pharmacogenomics,” xPharm: The Comprehensive Pharmacology Reference, pp. 1–3, 2007. View at Publisher · View at Google Scholar
  • Sue A Shapses, Yvette R. Schlussel, and Mariana Cifuentes, “Drug–Nutrient Interactions That Impact on Mineral Status,” Handbook of Drug-Nutrient Interactions, pp. 537–571, 2009. View at Publisher · View at Google Scholar
  • Jose de Leon, “The future (or lack of future) of personalized prescription in psychiatry,” Pharmacological Research, vol. 59, no. 2, pp. 81–89, 2009. View at Publisher · View at Google Scholar
  • D. Goldstaub, R. Favis, C. M. Bromley, W. Liu, F. Gheyas, N. Cohen, A. Prokop, D. Wang, C. Lopez-Correa, B. Fijal, A. Tchelet, S. Close, A. Snapir, and J. B. Singer, “Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group,” Pharmacogenomics Journal, vol. 9, no. 1, pp. 14–22, 2009. View at Publisher · View at Google Scholar
  • Jose de Leon, “Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders,” Neuropsychopharmacology, vol. 34, no. 1, pp. 159–172, 2009. View at Publisher · View at Google Scholar
  • Indra Neil Sarkar, “Biomedical informatics and translational medicine,” Journal of Translational Medicine, vol. 8, 2010. View at Publisher · View at Google Scholar
  • Martin C. Robson, Wyatt G. Payne, Yvonne N. Pierpont, Terry E. Wright, Charlotte A. Smith, Francis Ko, and M. Georgina Uberti, “Individualized, targeted wound treatment based on the tissue bacterial level as a biological marker,” American Journal Of Surgery, vol. 202, no. 2, pp. 220–224, 2011. View at Publisher · View at Google Scholar